M
MiRXES
Biotechnology, Cancer Diagnostics, Health Care, Life Science
About MiRXES
MiRXES is a biotechnology startup that operates in the healthcare sector, specifically focusing on the diagnosis and treatment of cancer and other diseases. The company's primary mission is to leverage scientific advancements to combat cancer, a disease that affects one in four people globally.
MiRXES operates in the medical diagnostics market, providing innovative solutions that range from discovery tools and services to diagnostic tests. These tests are designed to detect a variety of conditions, including cancer, cardiovascular diseases, metabolic disorders, and infectious diseases. The company's solutions are designed to enable early action, which is critical in managing these conditions effectively.
The company's business model revolves around the development and commercialization of these diagnostic tests. They generate revenue by selling these tests to healthcare providers and institutions. In addition, they also offer precision oncology services, which involve tailoring cancer treatment plans based on the individual genetic makeup of the patient's tumor. This personalized approach to cancer treatment is becoming increasingly popular and could represent a significant growth opportunity for the company.
MiRXES serves a diverse range of clients, including hospitals, clinics, and other healthcare providers. The company's solutions are designed to be used in a clinical setting, helping healthcare professionals to diagnose diseases early and accurately, thereby improving patient outcomes.
In summary, MiRXES is a biotech startup that uses science to fight cancer and other diseases. They develop and sell diagnostic tests and offer precision oncology services to healthcare providers, aiming to enable early action and improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Singapore, Singapore
- Listing
- IPO 2025
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
VentureCraft
Series A1 investor entered at this stage
MiRXES Innovation
Series B and later13 investors entered at this stage
- CFCR-CP Life Science Fund
Rock Springs Capital- CVCCBI Tech Venture
EDBI
Keytone Ventures
Charoen Pokphand
CCB International
CDG Invest Growth- NCNew Horizons Venture Capital
Mitsui Global Investment- BPBeijing Fellow Partners
- NVNHH Ventures
CBC Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about MiRXES on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MiRXES on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.